4-8-19 PHAS +36.4% (receives FDA Breakthrough Therapy
0
0
0
4-8-19 PHAS +36.4% (receives FDA Breakthrough Therapy
Companies trading higher in after hours in reaction to news: PHAS +36.4% (receives FDA Breakthrough Therapy designation for PB2452 for the reversal of the antiplatelet; provided immediate and sustained reversal of ticagrelor antiplatelet effects in ph I trial),